List view / Grid view
9 May 2010 | By EPR
Biopharmaceuticals is a rapidly growing sector of the pharmaceutical industry. Major pharmaceutical companies have recognised this trend in recent years and defined ambitious targets for the proportion of their pipeline that is expected to be filled by novel biopharmaceuticals. It is inevitable that many of the scientists involved with small-molecule…
9 May 2010 | By Sheraz Gul, Vice President, European ScreeningPort GmbH
In this article, an overview regarding advances in assay formats for specific target classes and options that should be considered when considering hardware will be given. There has been a significant growth in the assay and automation technologies that are available for compound screening activities and it is essential to…
9 May 2010 | By EPR
The American Society for Mass Spectrometry (ASMS) was formed in 1969 to promote and disseminate knowledge of mass spectrometry and allied topics. Membership includes over 7,500 scientists involved in research and development. Members come from academic, industrial and governmental laboratories. Their interests include advancement of techniques and instrumentation in mass…
9 May 2010 | By Professor Nicolas Abatzoglou, Chair, PAT in Pharmaceutical Engineering, Department of Chemical and Biotechnological Engineering, Université de Sherbrooke
Process analytical technologies (PAT) are mature and well advanced in the classical chemical industry. Many successful industry/university R&D collaborations are aimed at the development of analytical methods and their application in process control. However, PAT in the pharmaceutical industry is a rather new field. It is precisely this latter reality…
9 May 2010 | By EPR
The ISSCR Annual Meeting offers inspired research, new perspectives and networking with stem cell professionals from around the world. It creates a platform for the exchange of theoretical and applied information and skills, providing delegates with perspective, training and a forum to analyse the latest data.
9 May 2010 | By Paul D. Andrews, Drug Discovery Unit, College of Life Sciences, University of Dundee
They are only four years old and are getting everyone very excited; they were Science Magazine’s ‘Breakthrough of the Year 2008’ and Nature’s ‘Method of the Year 2009.’ Their discoverer, Shinya Yamanaka, shared the Lasker Award last year and is no doubt touted for a future Nobel Prize. ‘They’ are…
22 February 2010 | By
LGC is an international science-based company located in South West London. A progressive and innovative enterprise, LGC operates in socially responsible fields underpinning the health, safety and security of the public, and regulation and enforcement for UK government departments and blue chip clients. Our products and services enable our customers…
22 February 2010 | By Peter Ghazal, Professor of Molecular Genetics and Biomedicine, University of Edinburgh and Head of Division of Pathway Medicine and Associate Director of Centre for Systems Biology, Edinburgh, Al Ivens, Head of Data Analysis, Fios Genomics Ltd and Thorsten Forster, Statistical Bioinformatician, Division of Pathway Medicine, University of Edinburgh
In conventional pharmacogenomic studies, genetic polymorphisms (including single nucleotide and copy number variations) are elucidated from case-control distribution of individuals usually representing ethnicity, severity of disease, and positive or negative response to treatment. However, the interpretation of a single genetic marker in this context is complicated, as the same marker…
22 February 2010 | By
Over the past decade we have seen a significant realignment of activities associated with drug discovery and this will continue for a multitude of reasons. Within the pharmaceutical industry we have seen significant changes e.g. a decrease in the numbers of drugs that are being approved by the regulatory authorities…
22 February 2010 | By
It would be fair to say that these past 12 months have been a watershed year for stem cell science. In years to come we may look back on 2009 and recognise it as the year in which nascent areas of science, medicine and technology came together to slowly nudge…
Innovative drug delivery technologies are key components of drug development, with commercial and intellectual values. PEGylation is an excellent example of a delivery system that has scientific and multi-billion dollar commercial importance due to the remarkable improvement in the circulatory half lives of therapeutics, especially for proteins and peptides but…
22 February 2010 | By
For decades microbiological quality has remain dormant while the pharmaceutical industry has continued to evolve. Compendial methods and limits, while now generally harmonised throughout the world, still reflect the same methods utilised 100 years ago. Although there is more clarification around the number and types of organisms permitted in products…
22 February 2010 | By
The Centre for Process Analytics and Control Technology (CPACT) is a unique industry-driven multi-disciplinary research and development club that was formed in 1997 by the Departments of Pure and Applied Chemistry at the University of Strathclyde, the Department of Chemical and Process Engineering at the University of Newcastle and the…
22 February 2010 | By
Disorders of the immune systems leading to chronic inflammation and allergies are increasing in modern societies. While the possible causative factors are both environmental and nutritional, prevention and even curative options may be derived from our diet. Because background levels of cytokine expression in the general population are generally low,…
22 February 2010 | By
Pittcon 2010 will again offer the latest advances in laboratory instrumentation, supplies and services; comprehensive solutions for research problems; new methodologies and techniques for improved productivity; and a wide range of educational opportunities.
